Prof. Guang Biao Zhou, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Prof. Guang-Biao Zhou is a renowned cancer biologist and Deputy Director of the State Key Laboratory of Molecular Oncology at the National Cancer Center, Chinese Academy of Medical Sciences. His research focuses on 🫁 environmental lung carcinogenesis and cancer therapeutics, exploring the roles of genomic changes and non-coding RNAs in pollution-induced lung cancer. He has identified key factors like AhR, CXCL13, and CDC34 in tobacco and air pollution-related cancer pathways. 📚 With over 150 peer-reviewed publications, Dr. Zhou also serves as Executive Deputy Editor-in-Chief of Frontiers of Medicine and CAE Transactions on Medicine.
Publication Profile
Scopus
Orcid
🎓 Education & Qualifications
Prof. Guang-Biao Zhou earned his MD and Ph.D. in Medicine from the prestigious School of Medicine at Shanghai Jiao Tong University, Shanghai, China 🏛️. His academic training spanned from August 25, 2000, to July 1, 2003, equipping him with a solid foundation in medical science and research 🧬. This rigorous education laid the groundwork for his future contributions to oncology, particularly in environmental lung carcinogenesis and therapeutic innovation 🫁. Prof. Zhou’s qualifications reflect both academic excellence and a strong commitment to advancing medical knowledge 📚, shaping his path as a leading figure in cancer biology
💼 Professional Experience
Prof. Guang-Biao Zhou has held esteemed positions across leading Chinese research institutions. Since October 2018, he has been serving as a Professor at the State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences in Beijing 🏥. Prior to this, from 2009 to 2018, he was a Professor at the State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences 🧫. His earlier tenure from 2005 to 2009 was at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 🧬, marking a strong trajectory in biomedical research leadership
Research Focus
Prof. Dr. Guang-Biao Zhou is a leading researcher in the fields of lung cancer biology 🫁, molecular oncology 🧬, and immunotherapy 💉. His work focuses on the molecular mechanisms of tumor progression, such as metabolic reprogramming, apoptosis, and immune regulation. He has contributed to high-impact studies involving non-small cell lung cancer, cancer vaccine development, PD-L2-mediated immune responses, and thalassemia treatments. His interdisciplinary approach bridges genomic regulation, mitochondrial-associated cell death, and drug resistance pathways, aiming to improve prognostic markers and therapeutic targets. Zhou’s research is frequently published in top-tier journals like Molecular Cell, Nature Biomedical Engineering, and Cell Discovery.
Conclusion
Prof. Guang-Biao Zhou is highly suitable for the Research for Best Researcher Award. His work not only advances scientific understanding but also offers practical implications for improving global health outcomes.
Publication Top Notes
-
🧬 Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer – Cancer Letters, 2024 | 📅 2024 | DOI: 10.1016/j.canlet.2024.216929
-
⚡ CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in NSCLC – Cell Discovery, 2024 | 📅 2024 | DOI: 10.1038/s41421-023-00633-0
-
🧪 10,11-Dehydrocurvularin attenuates inflammation via NLRP3 suppression – Chinese Journal of Natural Medicines, 2023 | 📅 2023 | DOI: 10.1016/S1875-5364(23)60418-2
-
🌫️🧬 Air pollution, EGFR mutation, and cancer initiation – Cell Reports Medicine, 2023 | 📅 2023 | DOI: 10.1016/j.xcrm.2023.101046
-
🌿✨ Corrigendum: Promising anticancer activities of Centipeda minima compounds – Phytomedicine, 2023 | 📅 2023 | DOI: 10.1016/j.phymed.2022.154472
-
🧠🧬 Alternative splicing of FAK in pancreatic and breast neuroendocrine tumors – Frontiers of Medicine, 2023 | 📅 2023 | DOI: 10.1007/s11684-023-1009-7
-
🛡️🧫 CD47 in tumor immune evasion and targeted therapy – Journal of Sichuan Univ. (Med Sci), 2023 | 📅 2023 | DOI: 10.12182/20230560101
-
🧪🧬 Nuclear AhR and membranous PD-L1 predict PD-1 response in NSCLC – Signal Transduction & Targeted Therapy, 2023 | 📅 2023 | DOI: 10.1038/s41392-023-01416-5
-
🚬🛡️ Tobacco carcinogen induces IDO1 and immune suppression – Signal Transduction & Targeted Therapy, 2022 | 📅 2022 | DOI: 10.1038/s41392-022-01127-3
-
📢🧬 Correction: AhR mediates tobacco-induced PD-L1 and immunotherapy response – Nature Communications, 2022 | 📅 2022 | DOI: 10.1038/s41467-022-30871-x